CM vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is concerning, highlighted by a weak Piotroski F-Score of 2/9, indicating significant deterioration in fundamental financial strength. While the company exhibits explosive growth (Earnings +46.6% YoY) and a strong track record of earnings beats, these are countered by a severely bearish technical trend (10/100) and a current price that has already exceeded analyst target prices. The stock trades at a premium to its Graham Number ($89.37) but remains well below its growth-based intrinsic value ($207.09), suggesting a conflict between short-term health risks and long-term growth potential.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
CM vs JPM: Head-to-Head Comparison
This page compares Canadian Imperial Bank of Commerce (CM) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.